Tocilizumab Cuts Progression to Ventilation or Death in COVID - 19
But death from any cause by day 28 in those hospitalized with COVID - 19 pneumonia did not differ for tocilizumab versus placebo (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - December 18, 2020 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Emergency Medicine, Journal, Source Type: news

Tocilizumab Cuts Progression to Ventilation or Death in COVID-19
FRIDAY, Dec. 18, 2020 -- Tocilizumab reduces the risk for progression to ventilation or death among hospitalized patients with COVID-19 pneumonia, according to a study published online Dec. 18 in the New England Journal of Medicine. Carlos Salama,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2020 Category: Pharmaceuticals Source Type: news

Dec 4 2020 This Week in Cardiology Dec 4 2020 This Week in Cardiology
COVID vaccines, tocilizumab, finerenone, type 2 MI care, coronary CTA, and sotagliflozin are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 4, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Could IL-6 Inhibition Benefit Patients With Severe COVID-19? Could IL-6 Inhibition Benefit Patients With Severe COVID-19?
Researchers behind a new observational study say they have found a ' signal ' of benefit for interleukin-6 inhibitors such as tocilizumab in reducing in-hospital mortality in COVID-19 patients.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 2, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Hemophagocytic Lymphohistiocytosis in a Patient With COVID-19 Hemophagocytic Lymphohistiocytosis in a Patient With COVID-19
This patient with hemophagocytic lymphohistiocytosis secondary to COVID-19 responded after one dose of the IL-6 receptor antagonist tocilizumab.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 2, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

Tocilizumab for patients admitted to ICU with COVID-19 Pneumonia (Adults), NHS ENgland
Following early positive signals of benefit from the immune modulation therapy domain of the REMAP-CAP platform trial, a UK wide position statement has been agreed to support off-label prescribing and access to tocilizumab, administered intravenously, for eligible COVID positive patients in the intensive care setting. The interim position statement will be reviewed as further evidence becomes available, including from the REMAP-CAP trial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 1, 2020 Category: Consumer Health News Source Type: news

Interim Position Statement: Tocilizumab for patients admitted to ICU with COVID-19 pneumonia (adults), Chief Medical Officer
Following data from the REMAP-CAP trial, this position statement provides information to clinicians and healthcare organisations considering prescribing tocilizumab for COVID-19 pneumonia when the internal governance arrangements are in place. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 26, 2020 Category: Consumer Health News Source Type: news

' Dramatic' Inflammation Reduction After OHCA With Tocilizumab'Dramatic' Inflammation Reduction After OHCA With Tocilizumab
A pilot study showed reduced systemic inflammatory response and cardiac injury in out-of-hospital cardiac arrest patients, with the hope of affecting mortality and neurologic outcome in larger trials.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 24, 2020 Category: Intensive Care Tags: Cardiology News Source Type: news

IDSA Updates COVID Guidelines for Antibodies, Antivirals, Others IDSA Updates COVID Guidelines for Antibodies, Antivirals, Others
Infectious disease experts critically review evidence for use of bamlanivimab, address new data on remdesivir and tocilizumab, and comment on new findings for the Oxford University COVID-19 vaccine.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 23, 2020 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

Roche's Actemra Helps the Sickest COVID-19 Patients, Study Shows Roche's Actemra Helps the Sickest COVID-19 Patients, Study Shows
Roche ' s Actemra helped the sickest COVID-19 patients in a 303-patient study, the trial ' s lead investigator said on Thursday, bolstering what has been mixed evidence that the arthritis drug can be repurposed to help in the pandemic.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 23, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Tocilizumab: Arthritis drug may treat severe Covid
Early signs suggest it may help patients with severe breathing difficulties who are on ventilators. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 19, 2020 Category: Consumer Health News Source Type: news

Arthritis drug tocilizumab can help critically-ill Covid patients recover, trial finds
Patients given the drug in the REMAP-CAP trial, led by Imperial College London, were 87 per cent more likely to see their illness improve than those not given the drug. (Source: the Mail online | Health)
Source: the Mail online | Health - November 19, 2020 Category: Consumer Health News Source Type: news

Tocilizumab Stumbles as COVID-19 Treatment, Narrow Role Possible Tocilizumab Stumbles as COVID-19 Treatment, Narrow Role Possible
New randomized controlled trial data show tocilizumab has a narrow role at best for treating COVID-19.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 28, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news